SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in ...
Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer
Est. EPS $-0.05 · Revenue $0.00 · 2 analysts
Est. EPS $-0.05 · Revenue $36.13M · 1 analysts
Est. EPS $-0.20 · Revenue $36.13M · 1 analysts
Est. EPS $-0.05 · Revenue $0.00 · 1 analysts
| Metric | Latest | YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength. | QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes. |
|---|---|---|---|
| RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three). | $0 | — | — |
| Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day. | $-26.9M | +13.0% | -14.3% |
| Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials. | — | — | — |
| Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on). | — | — | — |
| Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales. | — | — | — |
| Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock. | $-28.4M | +19.8% | +14.2% |
| FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine. | — | — | — |
| Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe. | 1.4% | -86.6% | -34.0% |
| Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking. | 10.72x | +524.3% | +9.3% |
| Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground. | $78.3M | +303.2% | +27.3% |
| Metric | Annual (A vs E) | Annual Surprise | Quarter (A vs E) | Quarter Surprise |
|---|---|---|---|---|
| EPS Surprise | -0.25 vs -0.26 | +3.8% | -0.05 vs -0.04 | -11.1% |
| Revenue Surprise | $0 vs $32.0M | -100.0% | — | — |
| Date | Executive | Title | Security | Side | Shares | Price |
|---|---|---|---|---|---|---|
| Jun 16, 2026 | Stergiou Angelos M. | director, officer: President and CEO | Common Stock | A | 1,065,000 | — |
| Jan 7, 2026 | Varian John | director | Common Stock | A | 50,000 | — |
| Jan 7, 2026 | VAN NOSTRAND ROBERT L | director | Common Stock | A | 50,000 | — |
| Jan 7, 2026 | SCHEINBERG DAVID A | director | Common Stock | A | 50,000 | — |
| Jan 7, 2026 | CICIC DRAGAN | officer: SVP, Chief Development Officer | Common Stock | A | 300,000 | — |
| Name | Title | Compensation | Gender | Year Born | Status |
|---|---|---|---|---|---|
Angelos Stergiou | Founder, President, Chief Executive Officer & Director | USD 1,073,008 | — | 1976 | Active |
Dragan Cicic | Senior Vice President & Chief Development Officer | USD 662,734 | — | 1963 | Active |
John Thomas Burns | Senior Vice President & Chief Financial Officer | USD 630,592 | Male | 1985 | Active |
Andrew Elnatan | Senior Vice President of Regulatory Affairs, CMC & Quality | — | Male | — | Active |
Stacy Yeung | VP, General Counsel & Corporate Secretary | — | Female | — | Active |
SELLAS Life Sciences Group is a high-conviction buy ahead of the pivotal Phase 3 REGAL trial readout for GPS in AML. The unusually long REGAL trial timeline suggests GPS may be delivering a meaningful survival benefit in a high-unmet-need AML population. SLS is well-funded into 2027, with $138.3 million in cash and targeted spending aligned to upcoming binary catalysts.
- Final Analysis of Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia to be Conducted Following the 80 th Event - - 28 Patients Enrolled in Phase 2 Trial of SLS009 in Newly Diagnosed First-Line AML; Topline Data Expected in Q4 2026 - - Strong Preclinical Indications of Efficacy of SLS009 in Advanced Pancreatic Cancer Resistant to RAS inhibitors, Clinical Development Preparations Ongoing - - $138.3 Million in Cash and Cash Equivalents as of June 30, 2026 - NEW YORK, Aug. 11, 2026 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS'' or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today reported financial results for the second quarter ended June 30, 2026, and provided a corporate update. “The second quarter was an important period of execution for SELLAS as we continued to advance both of our lead clinical programs, GPS and SLS009,” said Angelos Stergiou, MD, ScD h.c.
SELLAS Life Sciences enters its pivotal REGAL readout with a transformed shareholder base, stronger balance sheet, and a new supply structure. Institutional ownership doubled to 36.34%, with average allocation rising, reflecting both new and existing holders increasing stakes ahead of the binary event. Passive and index-linked funds now dominate SLS's register, while multi-strategy and quant funds have exited, reducing volatility-driven trading around the catalyst.
SELLAS Life Sciences is at the center of a debate over its event-driven Phase 3 REGAL trial for GPS in AML CR2 patients. The extended REGAL timeline should not be interpreted as evidence of failure or success, given its event-driven design and recent protocol amendments. FDA-approved unlimited dosing and continued management confidence add nuance, but only final data will determine REGAL's outcome.
SELLAS Life Sciences Group Inc (NASDAQ:SLS) shares are trading lower Wednesday as investors take profits following the stock's strong longer-term uptrend, with broader risk appetite also softer across equities.
